



Clinical and genetic factors predicting response to therapy in patients with Crohn's disease

Marília Cravo^{1,2}, Paula Ferreira³, Patricia Sousa⁴, Paula Moura-Santos^{2,4},
Sonia Velho¹, Lurdes Tavares⁴, João Ramos Deus⁵, Paula Ministro⁶,
João Pereira da Silva⁷, Luis Correia^{2,4}, Jose Velosa^{2,4}, Rui Maio¹
and Miguel Brito³

Abstract

Aim: To identify clinical and/or genetic predictors of response to several therapies in Crohn's disease (CD) patients.

Methods: We included 242 patients with CD (133 females) aged (mean \pm standard deviation) 39 ± 12 years and a disease duration of 12 ± 8 years. The single-nucleotide polymorphisms (SNPs) studied were *ABCB1* C3435T and G2677T/A, *IL23R* G1142A, C2370A, and G9T, *CASP9* C93T, *Fas* G670A and LgC844T, and *ATG16L1* A898G. Genotyping was performed with real-time PCR with Taqman probes.

Results: Older patients responded better to 5-aminosalicylic acid (5-ASA) and to azathioprine (OR 1.07, $p=0.003$ and OR 1.03, $p=0.01$, respectively) while younger ones responded better to biologicals (OR 0.95, $p=0.06$). Previous surgery negatively influenced response to 5-ASA compounds (OR 0.25, $p=0.05$), but favoured response to azathioprine (OR 2.1, $p=0.04$). In respect to genetic predictors, we observed that heterozygotes for *ATG16L1* SNP had a significantly higher chance of responding to corticosteroids (OR 2.51, $p=0.04$), while homozygotes for *Casp9* C93T SNP had a lower chance of responding both to corticosteroids and to azathioprine (OR 0.23, $p=0.03$ and OR 0.08, $p=0.02$). TT carriers of *ABCB1* C3435T SNP had a higher chance of responding to azathioprine (OR 2.38, $p=0.01$), while carriers of *ABCB1* G2677T/A SNP, as well as responding better to azathioprine (OR 1.89, $p=0.07$), had a lower chance of responding to biologicals (OR 0.31, $p=0.07$), which became significant after adjusting for gender (OR 0.75, $p=0.005$).

Conclusions: In the present study, we were able to identify a number of clinical and genetic predictors of response to several therapies which may become of potential utility in clinical practice. These are preliminary results that need to be replicated in future pharmacogenomic studies.

Keywords

Crohn's disease, clinical genetic predictors, response to therapy

Received: 6 August 2013; accepted: 14 December 2013

Introduction

Crohn's disease (CD) is a chronic and relapsing condition, with the majority of patients experiencing a progressive and disabling course over time.^{1,2} Management of disease is complex and should take into account several factors such as disease location, activity, and behaviour.³ Additional disease aspects that make management difficult are the lack of correlation between severity of clinical symptoms and severity of intestinal inflammation and the difficulty in predicting a patient's clinical course and the individual response to a given treatment.

According to ECCO guidelines, 5-aminosalicylic acid (5-ASA) compounds could be used to treat

patients with mild-to-moderate ileocecal disease, whereas the use of azathioprine/6-mercaptopurine and/or anti-tumour necrosis factor (TNF) therapy is

¹Hospital Beatriz Angelo, Loures, Portugal

²Faculdade de Medicina da Universidade de Lisboa, Lisboa, Portugal

³Escola Superior de Tecnologias da Saude, Lisbon, Portugal

⁴Hospital Santa Maria, Lisboa, Portugal

⁵Hospital Fernando da Fonseca, Amadora, Portugal

⁶Hospital S Teotónio, Viseu, Portugal

⁷Instituto Português de Oncologia, Lisboa, Portugal

Corresponding author:

Marília Cravo, Hospital Beatriz Angelo, Av Carlos Teixeira n3, Loures, 2674-514, Portugal.

Email: marilia.cravo@sapo.pt

recommended for patients with moderate to severe disease who relapse after responding to steroids.³

In the past years, numerous efforts have been made with the aim of identifying early predictors of aggressive disease⁴⁻⁶ because, intuitively, patients presenting indicators of bad outcome at diagnosis would be the ideal candidates for early and more aggressive therapy in order to avoid long-term structural damage. However, patients who present with disease bad prognostic factors are not necessarily those who will respond better or worse to certain therapies. Although tailored therapy in CD is still far from reality, reliable prediction of response to treatment, combined with clinical indicators of aggressive disease, could allow a better selection of candidates for treatment, allowing the choice of not only the most effective therapies but also the less toxic ones. It is certainly important to remember that, according to previous studies,^{7,8} 30% of CD patients will have a mild disease course and will never need corticosteroids.

Previous studies have mainly focused on clinical predictors of response to biologicals. Short duration of disease is probably the single most important factor of response to anti-TNF agents and perhaps to azathioprine as well.⁹⁻¹¹ Some found better responses to biologicals in nonsmoking patients with recent onset and colonic disease, while others could not confirm these observations.¹²⁻¹⁵ A high value of basal C-reactive protein also seems to be a predictive factor of response to biologicals.¹⁶

As well as clinical and laboratory predictors, genetics could also influence patients' individual response to a drug.^{17,18} So far, pharmacogenomic research in inflammatory bowel disease has witnessed only modest success and sometimes conflicting results, mainly because response to treatment in this disease is very heterogeneous as it is influenced by many factors, such as disease duration, behaviour, and severity, which certainly interact with genetic variables and modulate response to treatment.¹⁹⁻²¹ While some authors reported that carriers of *ABCBI* single-nucleotide polymorphisms (SNPs) present a worse response to azathioprine or corticosteroids, others could not confirm these observations.²²⁻²⁵ *ABCBI* codes for the ATP-dependent membrane efflux transporter P-glycoprotein 1, which is expressed in various cells including in those in the gastrointestinal tract, which is responsible for resistance to a number of structurally and functionally unrelated drugs. *IL23R* has been recently implicated in the pathogenesis of CD. Although previous studies found that SNPs in this gene could increase susceptibility to develop CD,²⁶ few studies explored the association between these SNPs and phenotype or response to therapy in patients with inflammatory bowel disease.^{18,27,28} *Caspase9*, *Fas*, and *fas ligand*

encode for proteins involved in apoptosis, which has been shown to be defective in CD. Hlavaty et al.^{29,30} observed that carriers of SNPs of genes involved in apoptosis, responded less frequently to biologicals. Finally, *ATG16L1* is involved in autophagy, a key pathway for innate immunity and important for maintaining the epithelial barrier. Several drugs already used in the treatment of CD might exert at least part of their effect through the regulation of autophagy.³¹ A recently published study found an association between SNPs in this gene and response to corticosteroids, azathioprine, and biologicals.³²

The primary aim of the present study was to identify clinical and/or genetic factors that, alone or in combination, could predict response of CD patients to several therapies. Our secondary end point was to distinguish between those patients who will be in remission with azathioprine only from those who will need escalation to anti-TNF agents.

Materials and methods

This was a multicentre study with participating hospitals from Central Portugal. Informed consent was obtained from all patients entering the study, which was approved by Scientific and Ethical committees of the several participating hospitals.

Patients with the diagnosis of CD³³ were classified according to the Montreal classification³⁴ based on age at diagnosis (A), location (L), and behaviour (B). Disease modifiers were also considered: L4 when the upper digestive tract was involved and P for perianal involvement. No families with CD were included in the present series. Phenotypic characteristics retrospectively collected from charts included demographic data, age of disease onset, disease extension, and behaviour, time of follow up, smoking habits, presence of extraintestinal manifestations, and previous therapies including surgery. All phenotypic data were collected in a blinded fashion to the results of the genotypic data.

Patients were selected to enter the study if a definitive classification in terms of response to a specific drug could be clearly obtained after reviewing the chart and interviewing the patient at the moment of entering the study. Patients were considered responders if they presented long-term sustained remission, defined as a Harvey Bradshaw Index (HBI) lower than 4, lasting at least 1 year after a certain therapy was started, not needing steroids, surgery, or escalation of therapy to biologicals for those taking azathioprine or switch to another biological (infliximab vs. adalimumab) for those on biologicals. Patients requiring the addition or switching to other therapies, corticosteroids or surgery before 1 year were considered nonresponders. If a clear distinction between these two scenarios was not

possible for a specific drug, the patient was not considered either as a responder or as a nonresponder at least for this drug. Because our secondary end point was to distinguish between patients who responded to azathioprine from those who came to require biologicals, if a patient had a clinical remission for less than 1 year with azathioprine but came to require biologicals, he or she was considered a nonresponder to azathioprine.

Decision to switch therapy was made by the treating physician. HBI was calculated after a new therapy was started until the drug was discontinued or until end of follow up. Optimization of dose and/or interval of administration in patients on biologicals, was considered as therapy optimization and not as non-response. Biological parameters such as C-reactive protein levels or endoscopic response were not used to classify patients as responders or nonresponders because identification of these data on the precise moment on which a specific therapy was started was not clear in a large number of patients.

For steroids, only short-term response was considered. Steroid dependence was defined as recurrent flare up on withdrawal of glucocorticoids or as the need for glucocorticoids treatment twice within 6 months. Patients were considered refractory to steroids when no remission was obtained with a dose of 1 mg/kg during a period of at least 4 weeks.

DNA extraction and genotyping

Blood samples were taken from all study participants, and genomic DNA was isolated from peripheral blood using a DNA blood mini kit from Quiagen (Hiden, Germany) according to the manufacturer's guidelines. A total of 10 SNPs were studied: *ABCB1* C3435T (rs1045642) and G2677T/A (rs2032582), *IL23R* G1142A (rs11209026), C2370A (rs10889677), G43045A (rs1004819) and G9T (rs1884444), *CASP9* C93T (rs4645983), *Fas* G670A (rs1800682), *FasLg* C844T (rs763110), and *ATG16L1* A898G (rs2241880). All genotypes were determined using real-time PCR with TaqMan Pre-Designed SNP Genotyping Assays (Applied Biosystems, USA), except for *Fas* G670A and *FasLg* C844TT, which were determined using Custom TaqMan SNP genotyping Assays probes (Applied Biosystems). To perform the genotype analysis, the target fragments were amplified in 20- μ l reaction mixture containing 10 μ l TaqMan Universal PCR Master Mix, 1 μ l primers, 5 μ l Milli-Q water, and 4 μ l DNA. Real-time PCR was conducted using a iCycler iQ[®] Multicolor Real-Time PCR Detection System (BIO-RAD) with the following thermal cycling program: 10 min at 95°C and 50 cycles of 15 s at 92°C and 1 min at 60°C.

Statistical analysis

Statistical analysis was performed using SPSS version 14.0 (SPSS, Chicago, IL, USA) and SNPAssoc 1.6 package in R software. Data were expressed as mean \pm standard deviation, number of subjects (%), or odds ratio (OR) with 95% confidence interval (CI). Primary analyses were performed using chi-squared test and univariate logistic regression. Multivariate logistic regression was performed to adjust for potential confounding variables. Receiver operating characteristic (ROC) curves were plotted for multivariate models, and sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and area under the curve (AUC) were calculated. Whenever the AUC value was under 0.65, the model performance was considered unacceptably low and data are not shown. Association between outcome and SNP was analysed with SNPAssoc library in R and SPSS 19 (IBM SPSS statistics). Different inheritance models (dominant, recessive, log-add, and overdominant) were considered and were presented as eligible. Haplotype analysis was performed for *ABCB1* C3435T and *ABCB1* G2677T/A. To adjust for multiple testing, a Bonferroni correction was applied. Statistical significance was established for $p < 0.05$. Differences in genotypic and allelic frequencies and Hardy–Weinberg tests were performed using GENEPOP Web version 4.0.10 program. To obtain the exact p -value of the Hardy–Weinberg equilibrium, the Markov Chain method (Guo and Thompson, 1992) with a dememorization number of 1000, 100 batches, and 1000 iterations per batch was used. The p -value returned by this method is calculated as the sum of the probabilities of all tables and its standard error. Genotypic frequencies are under Hardy–Weinberg equilibrium when $p > 0.001$.

Results

A total of 242 CD patients were eligible to enter the study; mean follow-up period was 2.5 years. There were no patients treated according to the top-down strategy. Because the criteria used to consider patients as responders or nonresponders required sustained clinical remission for 1 year or more, there were only four patients who were considered responders simultaneously to azathioprine and biologicals. The demographic, clinical, and response to therapy data are shown on Table 1.

Allelic and genotypic frequencies

Allelic and genotypic frequencies for all the studied SNPs are shown in Table 2. The genotypic frequencies of all SNPs did not deviate significantly from those

Table 1. Demographic and clinical data from patients included in the study

Characteristic	Study population (n = 242)
Gender	
Male	109 (45)
Female	133 (55)
Age (years)	39 ± 12.8
Duration of disease (years)	11.8 ± 8.4
Duration of follow up (years)	2.5 ± 3.2
Age of disease onset	
A1	28 (12)
A2	183 (75)
A3	31 (13)
Location of disease	
L1	54 (22)
L2	48 (20)
L3	140 (58)
L4	20 (8)
Behaviour of disease	
B1	110 (45)
B2	93 (39)
B3	39 (16)
Perianal involvement	90 (39)
Previous surgery	
Yes	64 (26)
No	178 (74)
Perianal procedures	38 (16)
Smoking habits	
Yes	66 (27)
No	141 (58)
Unknown	35 (14)
Extraintestinal manifestations	
Yes	79 (33)
No	163 (67)
5-Aminosalicylic acid	
Yes	29 (48/12)
No	31 (52)
Corticosteroids	
Yes	107 (74/44)
No	37 (26) ^a
Azathioprine	
Yes	90 (56/41)
No	70 (44)
Biologicals	
Yes	81 (81/33)
No	19 (19)

Values are n (%), mean ± standard deviation, or % responders to drug/% responders of total.

^aResponse to corticosteroids refers to short-term (1 month) response. Of these 37 patients, seven were refractory to corticosteroids and 30 were corticoid dependent.

Table 2. Genotypic frequencies, allelic frequencies, and Hardy-Weinberg equilibrium

Polymorphism	Genotypes	Alleles	Hardy-Weinberg equilibrium
<i>ABCB1</i> C3435T			
CC (n = 71)	0.298		
CT (n = 100)	0.420	C	0.508
TT (n = 67)	0.282	T	0.492
			p = 0.0147
<i>ABCB1</i> G2677T/A			
GG (n = 66)	0.282		
GT + GA (n = 119)	0.517	G	0.527
TT + AA + TA (n = 53)	0.202	T/A	0.473
			p = 1.0000
<i>IL23R</i> G1142A			
GG (n = 193)	0.801		
GA (n = 47)	0.195	G	0.898
AA (n = 1)	0.400	A	0.102
			p = 0.4826
<i>IL23R</i> C2370A			
CC (n = 93)	0.389		
CA (n = 114)	0.477	C	0.628
AA (n = 32)	0.134	A	0.372
			p = 0.8902
<i>IL23R</i> G9T			
TT (n = 58)	0.244		
TG (n = 119)	0.500	T	0.494
GG (n = 61)	0.256	G	0.506
			p = 1.0000
<i>IL23R</i> C/T			
CC (n = 83)	0.353		
CT (n = 123)	0.523	C	0.615
TT (n = 29)	0.123	T	0.385
			p = 0.1353
<i>Casp9</i> C93T			
CC (n = 131)	0.567		
CT (n = 86)	0.372	C	0.753
TT (n = 29)	0.610	T	0.247
			p = 1.0000
<i>Fas</i> G670A			
GG (n = 44)	0.191		
GA (n = 120)	0.522	G	0.452
AA (n = 66)	0.287	A	0.548
			p = 0.5047
<i>Fas</i> LgC844T			
CC (n = 73)	0.319		
CT (n = 104)	0.454	C	0.546
TT (n = 52)	0.227	T	0.454
			p = 0.2317
<i>ATG16L1</i> A898G			
AA (n = 43)	0.297		
AG (n = 100)	0.437	A	0.406
GG (n = 86)	0.266	G	0.594
			p = 0.1750

There was no deviation from Hardy-Weinberg equilibrium.

expected under Hardy–Weinberg equilibrium ($p > 0.001$).

Associations between genetic polymorphisms and phenotypic characteristics

We observed that carriers for *IL23R* G9T and *IL23R* C2370A SNPs had less frequently upper GI involvement as compared to wild-type carriers (OR 0.4, 95% CI 0.2–0.82, $p = 0.008$, and OR 0.25, 95% CI 0.06–0.86, $p = 0.03$, respectively). Also, TT carriers for *FasLg* C844T SNP exhibited more often an inflammatory behaviour (B1) (OR 0.38, 95% CI 0.18–0.82, $p = 0.014$). No other significant associations were observed between the remaining SNPs and disease characteristics.

Associations between clinical characteristics, SNPs, and response to therapy

An analysis of associations between clinical variables and response to several drugs according to univariate analysis was performed. Only significant or near significant associations are displayed in Table 3.

We observed that older patients and those with a longer duration of disease responded better to 5-ASA compounds (OR 1.07, $p = 0.003$ and OR 1.16, $p = 0.002$, respectively). On multivariate analysis, after adjusting for age and previous surgery, disease duration remained statistically significant (OR 1.21, $p = 0.005$); however, age was no longer statistically significant.

The same trend was observed in respect to response to azathioprine and age (OR 1.03, $p = 0.01$), which means that there is a 3% increase in the chance of responding to azathioprine for each additional year of life. In respect to biologicals, an opposite trend was observed with a higher chance of response in younger patients ($p = 0.06$) and with more recent disease onset ($p = 0.008$). However, on multivariate analysis, both age and duration of disease lost significance.

Previous surgery negatively influenced response to 5-ASA compounds (OR 0.25, $p = 0.05$), while the opposite effect was observed in regard to azathioprine (OR 2.1, $p = 0.04$) (Table 3). In respect to perianal involvement, we observed that these patients did significantly worse on corticosteroids (OR 0.32, $p = 0.006$) (Table 3). No significant associations were found between disease behaviour, disease location including L4 involvement, smoking habits, presence of extraintestinal manifestations, and response to various therapies. Stricturing and penetrating phenotypes (B2 and B3, respectively) were more often associated with surgical therapy in contrast with inflammatory phenotype (B1) (OR 18.3, 95% CI 7.5–54.8, $p < 0.0001$).

Interestingly, previous therapies seemed to influence response to therapy in various ways (Table 3). Thus, previous 5-ASA users responded better to biologicals, although not reaching statistical significance (OR 2.86, 95% CI 0.90–8.94, $p = 0.06$). Previous corticosteroid therapy negatively influenced response to 5-ASA (OR 0.05, 95% CI 0.003–0.333, $p = 0.008$). Finally, previous use of biologicals decreased the chance of responding

Table 3. Association between clinical phenotypic characteristics and response to therapy according to univariate analysis

Characteristic	5-ASA ($n = 60$)	Corticosteroids ($n = 144$)	Azathioprine ($n = 160$)	Biologicals ($n = 100$)
Responders/nonresponders	29/31	107/37	90/70	81/19
Age	1.07 (1.02–1.14) $p = 0.003$	–	1.03 (1.006–1.06) $p = 0.01$	0.95 (0.90–1.00) $p = 0.06$
Duration of disease	1.16 (1.07–1.31) $p = 0.002$	–	–	0.91 (0.85–0.98) $p = 0.008$
Previous surgery	0.25 (0.05–0.96) $p = 0.05$	–	2.1 (1.04–4.49) $p = 0.04$	–
Perianal disease	–	0.32 (0.14–0.72) $p = 0.006$	–	–
Previous 5-ASA	–	–	–	2.86 (0.90–8.94) $p = 0.06$
Previous steroids	0.05 (0.03–0.33) $p = 0.008$	–	–	–
Previous biologicals	–	0.26 (0.11–0.60) $p = 0.002$	0.05 (0.02–0.13) $p = 1.26 \times 10^{-9}$	–

Values are OR (95% CI). OR < 1.00 , less responsive; OR > 1.00 , better response. Table only displays significant or near significant results. 5-ASA, 5-Aminosalicylic acid.

Table 4. Association between genetic polymorphism and response to therapy according to univariate analysis

Polymorphism and genotype	5-ASA (n = 60)	Corticosteroids (n = 144)	Azathioprine (n = 160)	Biologicals (n = 100)
Responders/nonresponders	29/31	107/37	90/70	81/19
<i>IL23R</i> G9T: GT	0.29 (0.08–1.03) <i>p</i> = 0.06	-	-	3.06 (0.91–10.4) <i>p</i> = 0.06
<i>Casp9</i> C93T: TT	-	0.23 (0.36–0.88) <i>p</i> = 0.03	0.08 (0.004–0.51) <i>p</i> = 0.02	-
<i>ABCB1</i> C3435T: TT	-	-	2.38 (1.13–5.02) <i>p</i> = 0.01	-
<i>ABCB1</i> G2677T/A: TT vs. G carrier	-	-	1.89 (0.94–3.81) <i>p</i> = 0.07	0.31 (0.08–1.07) <i>p</i> = 0.07

Values are OR (95% CI). OR < 1.00, less responsive; OR > 1.00, better response. Table only displays significant or near significant results. 5-ASA, 5-Aminosalicylic acid.

both to corticosteroids (OR 0.26, *p* = 0.002) and to azathioprine (OR 0.05, *p* = 1.26 × 10⁻⁹).

The associations between genetic polymorphisms and response to therapy on univariate analysis are shown on Table 4. We observed that heterozygotes for the polymorphic allele of *IL23R* G9T had a lower chance of responding to 5-ASA compounds (OR 0.29, *p* = 0.06) but a higher one of responding to biologicals (OR 3.06, *p* = 0.06).

Homozygotes for *Casp9* C93T SNP had a significantly lower chance of responding both to corticosteroids and to azathioprine (OR 0.23, *p* = 0.03 and OR 0.08, *p* = 0.02, respectively; Table 4). After adjusting for previous response to biologicals, gender, and *ATGL16L1*, the probability of responding to corticosteroids was even further decreased (OR 0.14, 95% CI 0.03–0.71 *p* = 0.014). A ROC curve was plotted for the previous model: 71.1% sensibility, 71.9% specificity, 54.9% PPV, 11.5% NPV, and an AUC of 0.778 was obtained (Figure 1).

In respect to the *ABCB1* C3435T SNP, we observed that TT carriers had a significantly higher chance of responding to azathioprine (OR 2.38, *p* = 0.01; Table 4). After adjusting for gender distribution, we observed that this association remained significant (OR 2.4, 95% CI 1.13–5.03 *p* = 0.019) and became even more significant after further adjustment for age and smoking habits (OR 3.22, 95% CI 1.13–5.03 *p* = 0.005). Model assessment with a ROC curve generated a 60.5% sensibility, 73% specificity, 39.5% PPV, 27% NPV, and an AUC of 0.687 (Figure 2).

The same was observed for the polymorphic allele carriers of the other SNP of this gene (*ABCB1* G2677T/A), although not reaching statistical significance (OR 1.89, *p* = 0.07). Carriers of both haplotypes had a higher chance of responding to azathioprine (OR 1.53, 95% CI 0.94–2.49, *p* = 0.08). The *ABCB1* G2677T/A SNP, as well as responding better to




Figure 1. Receiver operating characteristic curve for model assessment of the *Casp9* C93T SNP. Multivariate logistic regression model: dependent variable, therapy response to corticosteroids; independent variables, *Casp9* C93T SNP, gender, previous therapy with infliximab, and *ATGL16L1*.

azathioprine, had a significantly lower chance of responding to biologicals (OR 0.31, *p* = 0.07), which became significant after adjusting for gender (OR 0.75, 95% CI 0.24–0.63, *p* = 0.005). Adjusting for duration of disease also increased the strength of this association (OR 0.23, 95% CI 0.07–0.70, *p* = 0.01). When considering the ROC curve for the former model, 70.1% sensibility, 63.2% specificity, 65.7% PPV, 11.5% NPV, and an AUC of 0.714 was obtained (Figure 3).

We also examined whether there was any interaction between clinical and genetic predictors of response. As shown in Table 5, we observed that carriers for both *ABCB1* SNPs responded better to azathioprine only if




Figure 2. Receiver operating characteristic curve for model assessment of the *ABCB1* C3435T SNP
Multivariate logistic regression model: dependent variable, therapy response to azathioprine; independent variables, *ABCB1* C3435T SNP, gender, smoking habits, and age.




Figure 3. Receiver operating characteristic curve for model assessment of the *ABCB1* G2677T/A SNP
Multivariate logistic regression model: dependent variable, therapy response to biologics; independent variables, *ABCB1* G2677T/A SNP, gender, and disease duration.

they had an ileocolonic involvement as compared to isolated ileal or colonic disease.

Discussion

CD is a heterogeneous disease both in terms of clinical manifestations as well as in terms of response to

Table 5. Interaction between *ABCB1* haplotypes (C3435T and G2677T/A) and disease location

Haplotype	Ileal disease (L1)	Colonic disease (L2)	Ileocolonic disease (L3)
CG	1.00	1.00	1.00
TG	0.57 (0.11–3.10)	0.28 (0.02–3.63)	3.51 (1.02–11.99)*
CT	1.45 (0.17–12.07)	0.00	5.9 (1.28–22.19)*
TT	2.05 (0.62–6.43)	1.18 (0.40–3.52)	2.0 (0.98–4.09)

* $p = 0.01$.

therapy. Great effort has been dedicated to develop treatment algorithms with the aim of choosing the most effective treatment with less adverse effects and risks.^{35–39} In this sense, a number of previous studies tried to identify clinical,^{12–16,40} serological,^{41,42} or genetic^{17–25} predictors of response to several therapies available; however, so far, the results have not been very consistent across studies. One of the reasons for these discrepancies might result from what is considered response. In the present study, we decided to use long-term response (more than 1 year) because we believe that this concept is clinically more relevant. Thus, a patient who responds to azathioprine or biologicals at 2–3 months but later relapses with the need of corticosteroids or escalation of therapy was considered a nonresponder to this specific therapy.

In regard to predictors of response, we used both clinical and genetic markers. The latter may be more attractive because they do not change over time. However, in clinical practice they are of little value until their utility can be clearly demonstrated and validated in other studies. In contrast, clinical or phenotypic variables are more readily used in clinical practice.

In the present study, 25% of patients (60/242) were treated with 5-ASA: 29 of these responded to this therapy whereas the remaining 31 did not and required further escalation of therapy. Although overall this means a low number of patients (29/242, 12%), we think that it is certainly important to identify those patients who do very well on less aggressive and less toxic therapies. According to the last ECCO consensus,³ no treatment may be an option in patients with mild disease, because a systematic review of clinical trials⁴³ showed that 18% of patients (95% CI 14–24%) of patients entered remission with placebo alone. In line with these findings, it is plausible that these patients could be treated with 5-ASA compounds only.

Previous surgery was a negative predictor of response in regard to 5-ASA (OR 0.25), but previously operated patients had a twice-higher chance of responding to azathioprine (OR 2.1). Clinically, we are often faced with the patient who does not respond to medical therapy, needs surgery, and post operatively

has a mild course, further raising the question of whether, once the diseased segment is resected, he can be maintained on 5-ASA therapy or whether immunosuppression should be started. Our data strongly supports the latter.

In regard to corticosteroids we observed that previous therapy with biologicals was a negative predictor of response to both corticosteroids (OR 0.26) and to azathioprine (OR 0.05). These are important observations from a clinical point of view because patients who are on biologicals and relapse are often treated with corticosteroids.³ According to our results, this is not contraindicated but they are less likely to respond. Also, patients who are doing well on combination therapy and in whom we want to de-escalate therapy, the immunosuppressor (azathioprine) should preferentially be stopped.

Genetic polymorphisms included in the present study were chosen according to previous studies, which had shown some type of association with response to therapy. Although some previously reported associations could not be confirmed in the present study,^{23,29,30} we found some interesting associations in the sense that genotypes identified patients who were simultaneously less likely to respond to certain therapies but more prone to respond to others. Thus, individuals who are heterozygotic for *IL23R* G9T SNP were less likely to respond to 5-ASA (OR 0.29) but 3-times more likely to respond to biologicals (OR 3.06). TT carriers of *Casp9* C93T SNP had a significant reduction in the probability of responding both to corticosteroids and azathioprine (OR 0.23 and 0.08, respectively), while TT carriers for both *ABCB1* C3435T and *ABCB1* G2677T/A showed a higher chance of responding to azathioprine. Concomitantly, TT carriers for *ABCB1* G2677T/A had a 25% reduction in the probability of responding to biologicals, which might be relevant in clinical decisions. ROC curves were plotted to test the performance of each of these models. This analysis allowed us to assess the performance of each of these models including SNPs for the several genetic associations found in multivariate analysis and response to corticosteroids, azathioprine, and biologicals. AUC values close or higher than 0.70 are considered reasonable classifiers, further reinforcing the reliability of the associations found between SNPs tested and response to several therapies.

This study had some limitations that need to be addressed. A major drawback relies on the fact that response to drugs was evaluated retrospectively from data recorded in the charts. However, in our opinion, after having the perspective of long-term evolution and whether the patient came to require therapy escalation after a transitory response which lasted less than 1 year, evaluating the response to a specific drug is clinically

more relevant than evaluating short-term responses. Another limitation refers to the number of patients included in the study, which may be considered low for a pharmacogenomic study. Therefore, the data obtained in the present study can only be considered preliminary until prospectively validated in an independent cohort of CD patients.

In conclusion, in the present study we were able to identify a number of clinical predictors of response to several therapies available to treat CD patients, that might be of help in clinical practice, not only to select patients for more potent therapies such as immunosuppressors or biologicals, but also to less toxic ones such as 5-ASA compounds. In regard to genetic predictors, associations found are certainly promising but can only, at best, be considered hypothesis generating until these results are confirmed in larger populations.

Funding

This research was supported by Grupo de Estudo da Doença Inflamatória Intestinal (2009–2012).

Conflict of interest

The authors declare that there is no conflict of interest.

References

1. Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn's disease. *Inflamm Bowel Dis* 2002; 8: 244–250.
2. Thia KT, Sandborn WJ, Harmsen WS, et al. Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort. *Gastroenterology* 2010; 139: 1147–1155.
3. Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. *J Crohns Colitis* 2010; 4: 28–62.
4. Beaugerie L, Seksik P, Nion-Larmurier I, et al. Predictors of Crohn's disease. *Gastroenterology* 2006; 130: 650–656.
5. Loly C, Belaiche J and Louis E. Predictors of severe Crohn's disease. *Scand J Gastroenterol* 2008; 43: 948–954.
6. Seksik P, Loftus EV, Beaugerie L, et al. Validation of predictors of 5-year disabling CD in a population-based cohort from Olmsted County, Minnesota, 1983–1996. *Gastroenterology* 2007; 132: A–17.
7. Froslie KF, Janhsen J, Moum BA, et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. *Gastroenterology* 2007; 133: 412–422.
8. Bokemeyer B, atalinic A, Klugmann T, et al. Predictive factors for a mild course of Crohn's colitis. *J Crohn's Colitis* 2009; 3: S82.
9. Colombel J-F, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. *Gastroenterology* 2007; 132: 52–65.

10. Schreiber S, Khaliq-Kareemi M, Lawrence IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. *N Engl J Med* 2007; 357: 239–250.
11. Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. *Gastroenterology* 2000; 119: 895–902.
12. Arnott IDR, McNeill G and Satsangi J. An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's disease. *Aliment Pharmacol Ther* 2003; 17: 1451–1457.
13. Vermeire S, Loius E, Carbonez A, et al. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease. *Am J Gastroenterol* 2002; 97: 2357–2363.
14. Parsi MA, Achkar JP, Richardson S, et al. Predictors of response to infliximab in patients with Crohn's disease. *Gastroenterology* 2002; 123: 707–713.
15. Su C and Lichenstein GR. Are there predictors of Remicade treatment success or failure? *Adv Drug Deliv Rev* 2005; 57: 237–245.
16. Reinish W, Wang Y, Oddens BJ, et al. C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post-hoc analysis from ACCENT I. *Aliment Pharmacol Ther* 2012; 35: 568–576.
17. Vermeire S, Van Assche G and Rutgeerts P. Role of genetics in prediction of disease course and response to therapy. *World J Gastroenterol* 2010; 16: 2609–2615.
18. Roberts RL and Barclay ML. Current relevance of pharmacogenetics in immunomodulation treatment of Crohn's disease. *J Gastroenterol Hepatol* 2012; 27: 1546–1554.
19. Mascheretti S, Hampe J, Croucher PJ, et al. Response to infliximab treatment in Crohn's disease is not associated with mutations in the CARD15 (NOD2) gene: an analysis in 534 patients from two multicenter, prospective GCP-level trials. *J Gastroenterol Hepatol* 2002; 12: 509–515.
20. Mascheretti S, Hampe J, Kuhbacher T, et al. Pharmacogenetic investigation of the TNF/TNF receptor system in patients with chronic active Crohn's disease treated with infliximab. *Pharmacogenomics J* 2002; 2: 127–136.
21. Vermeire S, Louis E, Rutgeerts P, et al. NOD2/CARD15 does not influence response to infliximab in Crohn's disease. *Gastroenterology* 2002; 123: 106–111.
22. Potocnik U, Ferkolj I, Glavac D, et al. Polymorphisms in multidrug resistance 1 (MDR1) gene are associated with refractory Crohn disease and ulcerative colitis. *Genes Immun* 2004; 5: 530–539.
23. Mendoza JL, Urcelay E, Lana R, et al. MDR1 polymorphism and response to azathioprine therapy in patients with Crohn's disease. *Inflamm Bowel Dis* 2007; 13: 585–5890.
24. Palmieri O, Latiano A, Valvano R, et al. Multidrug resistance 1 gene polymorphism are not associated with inflammatory bowel disease and response to therapy in Italian patients. *Aliment Pharmacol Ther* 2005; 22: 1129–1138.
25. Cucchiara S, Latiano A, Palmieri O, et al. Polymorphisms of tumor necrosis alpha but not MDR1 influence response to medical therapy in pediatric onset inflammatory bowel disease. *J Pediatr Gastroenterol Nutr* 2007; 44: 171–179.
26. Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. *Science* 2006; 314: 1461–1463.
27. Jurgens M, Laubender RP, Hartl F, et al. Disease activity, ANCA, and IL-23R genotype status determine early response to infliximab in patients with ulcerative colitis. *Am J Gastroenterol* 2010; 105: 1811–1819.
28. Jurgens M, Brand S, Laubender RP, et al. The presence of fistulas and NOD2 homozygosity strongly predict intestinal stenosis in Crohn's disease independent of IL23R genotype. *J Gastroenterol* 2010; 45: 721–731.
29. Hlavaty T, Pierik M, Henckarerts L, et al. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease. *Aliment Pharmacol Ther* 2005; 22: 613–616.
30. Hlavaty T, Ferrante M, Henckarerts M, et al. Predictive model for the outcome of infliximab therapy in Crohn's disease based on apoptotic pharmacogenetic index and clinical predictors. *Inflamm Bowel Dis* 2007; 13: 372–379.
31. Nys K, Agostinis P, Vermeire S, et al. Autophagy: a new target or an old strategy to the treatment of Crohn's disease? *Nat Rev Gastroenterol Hepatol* 2013; 10: 395–401.
32. Duraes C, Machado JC, Portela F, et al. Phenotype-genotype profiles in Crohn's disease predicted by genetic markers in autophagy related genes (GOIA study II). *Infl Bowel Dis* 2013; 19: 230–239.
33. Lennard-Jones JE. Classification of inflammatory bowel disease. *Scand J Gastroenterol Suppl* 1989; 225: 92–99.
34. Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. *Gut* 2006; 55: 749–753.
35. Feagan BG, Lemann M, Befrits R, et al. Recommendations for the treatment of Crohn's disease with tumor necrosis factor antagonist: an expert consensus report. *Inflamm Bowel Dis* 2012; 18: 152–160.
36. Ordas I, Feagan BG and Sandborn WJ. Early use of immunosuppressives or TNF antagonists for the treatment of Crohn's disease: time for a change. *Gut* 2011; 60: 1754–1763.
37. D'Haens GR. Top-down therapy for IBD: rationale and requisite evidence. *Nat Rev Gastroenterol Hepatol* 2010; 7: 86–92.
38. Colombel JF, Sandborn WJ, Reinisch W, et al. SONIC study Group. Infliximab, azathioprine, or combination therapy for Crohn's disease. *N Engl J Med* 2010; 362: 1383–1395.
39. D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression in patients with newly diagnosed Crohn's disease: an open randomized trial. *Lancet* 2008; 371: 660–667.
40. Allez M, Lemann M, Bonnet J, et al. Long-term outcome of patients with active Crohn's disease exhibiting extensive and deep ulcerations at colonoscopy. *Am J Gastroenterol* 2002; 97: 947–953.

41. Esters N, Vermeire S, Joossens S, et al. Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease. *Am J Gastroenterol* 2002; 97: 1458–1462.
42. Taylor KD, Plevy SE, Yang H, et al. ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease. *Gastroenterology* 2001; 120: 1347–1355.
43. Su C, Lichtenstein GR, Krok K, et al. A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease. *Gastroenterology* 2004; 126: 1257–1269.